Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy

MLA

Doisy, Laure, et al. “Efficacy of HIVEC in Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Are Contraindicated to BCG and in Patients Who Fail BCG Therapy.” International Journal of Hyperthermia, vol. 38, no. 1, Jan. 2021, pp. 1633–38. EBSCOhost, https://doi.org/10.1080/02656736.2021.2002435.

APA

Doisy, L., Cimier, A., Adypagavane, A., Walz, J., Marquette, T., Maubon, T., Rybikowski, S., Fakhfakh, S., Loverde, K., Mottet, N., Irani, J., Lechevallier, E., Rossi, D., & Pignot, G. (2021). Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy. International Journal of Hyperthermia, 38(1), 1633–1638. https://doi.org/10.1080/02656736.2021.2002435

Chicago

Doisy, Laure, Arnaud Cimier, Aurelien Adypagavane, Jochen Walz, Thibault Marquette, Thomas Maubon, Stanislas Rybikowski, et al. 2021. “Efficacy of HIVEC in Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Are Contraindicated to BCG and in Patients Who Fail BCG Therapy.” International Journal of Hyperthermia 38 (1): 1633–38. doi:10.1080/02656736.2021.2002435.